A Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for Single Dose Administration of TLC599 in Patients With Osteoarthritis (OA) of Knee
Latest Information Update: 24 Apr 2024
At a glance
- Drugs Dexamethasone (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Taiwan Liposome Company
- 18 May 2020 According to a TLC Biopharmaceuticals media release, data from this study were accepted as an abstract at Osteoarthritis Research Society International (OARSI) 2020 and published in the Osteoarthritis and Cartilage journal.
- 18 May 2020 Results published in the TLC Biopharmaceuticals media release
- 13 May 2020 According to a TLC Biopharmaceuticals media release, A selected abstract on subgroup analyses of this Phase II trial, which was scheduled for presentation at OARSI, has been published in Osteoarthritis and Cartilage.